TARGETING NNMT BY JERATININE E USING BIOANALYTICS TO TARGET PARKINSON'S DESEASE

Abstract

Parkinson's disease (PD), the second most common neurological ailment, is expected to become more common over the following three decades. Despite growing study, it is still difficult to get a precise diagnosis and the early phases of PD are still poorly understood. According to certain ideas, autointoxication may be the cause of Parkinson's disease as the blood-brain barrier prohibits charged substances from entering the brain and necessitates the existence of the nicotinamide N methyltransferase (NNMT) enzyme for neurotoxicity. It's interesting to note that NNMT activity is more apparent in Parkinson's patients' brains. The creation of certain inhibitors that block the NNMT enzyme may result in considerable improvements in primary and secondary PD preventive methods. The GEO collection gives researchers access to clinical and gene expression data from PD patients, allowing them to further examine this by analyzing patient outcomes and finding potential biomarkers for the illness. Our work connected genes with clinical data using protein-protein interactions (PPI) and functional enrichment approaches, using the GDC data portal to pinpoint the most important genes linked to PD. We identified genes with variable levels of expression between those with the PD mutation and those without by analyzing differential gene expression (DEGs). The importance of these genes in relation to PD was also quantified with the help of the GDC data website. In our investigation, The naturally occurring substance Jeratinine E showed promise as a therapeutic option. We learned more about the natural compound's' relation with NNMT with the help of molecular docking. This investigation states that Jeratinine E has a stronger affinity for NNMT. Jeratinine E's potential for further research was also assessed while accounting for its pharmacokinetic characteristics using ADMET analysis.